Literature DB >> 33087492

Multimodal CT or MRI for IV thrombolysis in ischemic stroke with unknown time of onset.

Kosmas Macha1, Philip Hoelter1, Gabriela Siedler1, Michael Knott1, Stefan Schwab1, Arnd Doerfler1, Bernd Kallmünzer2, Tobias Engelhorn1.   

Abstract

OBJECTIVE: To investigate differences in procedure times, safety, and efficacy outcomes comparing 2 different protocols to enable thrombolysis in the extended or unknown time window after stroke onset with either multimodal CT or MRI.
METHODS: Patients with ischemic stroke in the extended or unknown time window who received IV thrombolysis between January 2011 and May 2019 were identified from an institutional registry. Imaging-based selection was done by multimodal CT or MRI according to institutional treatment algorithms.
RESULTS: IV thrombolysis was performed in 100 patients (54.3%) based on multimodal CT imaging and in 84 patients (45.7%) based on MRI. Baseline clinical data, including stroke severity and time from last seen normal to hospital admission, were similar in patients with CT and MRI. Door-to-needle times were shorter in patients with CT-based selection (median [interquartile range] 45 [37-62] minutes vs 75 [59-90] minutes; mean difference [95% confidence interval (CI)] -28 minutes [-35 to -21]). No differences were detected regarding the incidence of symptomatic intracranial hemorrhage (2 [2.0%] vs 4 [4.8%]; adjusted odds ratio [aOR] [95% CI] 0.47 [0.08-2.83]) and favorable outcome at day 90 (25 [33.8%] vs 33 [42.9%]; aOR 0.95 [0.45-2.02]).
CONCLUSION: IV thrombolysis in ischemic stroke in the unknown or extended time window appeared safe in CT- and MRI-selected patients, while the use of CT imaging led to faster door-to-needle times. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with ischemic stroke in the extended or unknown time window, imaging-based selection for IV thrombolysis by multimodal CT compared to MRI led to shorter door-to-needle times.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33087492     DOI: 10.1212/WNL.0000000000011059

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  Imaging selection for reperfusion therapy in acute ischemic stroke beyond the conventional time window.

Authors:  Lauranne Scheldeman; Anke Wouters; Robin Lemmens
Journal:  J Neurol       Date:  2021-10-31       Impact factor: 4.849

2.  CT- versus MRI-Based Imaging for Thrombolysis and Mechanical Thrombectomy in Ischemic Stroke: Analysis from the Austrian Stroke Registry.

Authors:  Stefan Krebs; Alexandra Posekany; Alina Pilz; Julia Ferrari; Alexandra Bernegger; Christian Neumann; Siegfried Thurnher; Dominik Roth; Wilfried Lang; Marek Sykora
Journal:  J Stroke       Date:  2022-09-30       Impact factor: 8.632

3.  Updated Trends, Disparities, and Clinical Impact of Neuroimaging Utilization in Ischemic Stroke in the Medicare Population: 2012 to 2019.

Authors:  Jason J Wang; Casey E Pelzl; Artem Boltyenkov; Jeffrey M Katz; Jennifer Hemingway; Eric W Christensen; Elizabeth Rula; Pina C Sanelli
Journal:  J Am Coll Radiol       Date:  2022-04-25       Impact factor: 6.240

4.  Intelligent Algorithm-Based MRI Image Features for Evaluating the Effect of Nursing on Recovery of the Neurological Function of Patients with Acute Stroke.

Authors:  Ding Wang; Jingwei Dai
Journal:  Contrast Media Mol Imaging       Date:  2022-05-31       Impact factor: 3.009

5.  Evaluation of Functional Recovery Following Thrombectomy in Patients With Large Vessel Occlusion and Prestroke Disability.

Authors:  Maximilian I Sprügel; Jochen A Sembill; Svenja Kremer; Stefan T Gerner; Michael Knott; Stefan Hock; Tobias Engelhorn; Arnd Dörfler; Hagen B Huttner; Stefan Schwab
Journal:  JAMA Netw Open       Date:  2022-08-01

6.  Magnetic Resonance Imaging or Computed Tomography for Suspected Acute Stroke: Association of Admission Image Modality with Acute Recanalization Therapies, Workflow Metrics, and Outcomes.

Authors:  Urs Fischer; Mattia Branca; Leo H Bonati; Emmanuel Carrera; Maria I Vargas; Alexandra Platon; Zsolt Kulcsar; Susanne Wegener; Andreas Luft; David J Seiffge; Marcel Arnold; Patrik Michel; Davide Strambo; Vincent Dunet; Gian Marco De Marchis; Ludwig Schelosky; Gustav Andreisek; Filip Barinka; Nils Peters; Loraine Fisch; Krassen Nedeltchev; Carlo W Cereda; Georg Kägi; Manuel Bolognese; Stephan Salmen; Rolf Sturzenegger; Friedrich Medlin; Christian Berger; Susanne Renaud; Christophe Bonvin; Michael Schaerer; Marie-Luise Mono; Biljana Rodic; Marios Psychogios; Pasquale Mordasini; Jan Gralla; Johannes Kaesmacher; Thomas R Meinel
Journal:  Ann Neurol       Date:  2022-06-10       Impact factor: 11.274

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.